1. Surveillance should be offered to children at >5% risk of Wilms’s tumour. | D |
2. Surveillance should be offered only after review by a clinical geneticist. | D |
3. Surveillance should be carried out by renal ultrasonography every 3–4 months. | D |
4. Surveillance should continue until 5 years in all conditions except Beckwith–Wiedemann syndrome, Simpson–Golabi–Behmel syndrome and some familial Wilms’s tumour pedigrees, where it should continue until 7 years. | D |
5. Surveillance can be undertaken at a local centre, but should be carried out by someone with experience of paediatric ultrasonography. | D |
6. Screen-detected lesions should be managed at a specialist centre. | D |